Bailing Zu1, Yajuan Li, Xin Wang, Dali He, Zhenglan Huang, Wenli Feng. 1. Department of Clinical Hematology, Key Laboratory of Laboratory Medical Diagnostics Designated by the Ministry of Education, Chongqing Medical University, No. 1, Yixueyuan Road, Chongqing, 400016, PR China.
Abstract
BACKGROUND: MDR1 gene polymorphisms were demonstrated to be associated with interindividual variability of imatinib response for chronic myeloid leukemia (CML) patients in several studies; however, the results have been inconclusive. MATERIALS & METHODS: To clarify the effect of common MDR1 variants on clinical response to imatinib, we performed a meta-analysis to quantify the accumulated information from genetic association studies. After a thorough search of the published literature, we undertook a meta-analysis to evaluate the effect of MDR1 C1236T, G2677T and C3435T polymorphisms on imatinib response. RESULTS: Our pooled data showed a significant association between MDR1 C1236T polymorphism and the increasing risk of imatinib resistance in Asian CML patients. However, no significant association was found for the MDR1 G2677T or C3435T polymorphisms in an Asian CML population as well as a Caucasian CML population. CONCLUSION: The synonymous MDR1 C1236T polymorphism might be a risk factor for nonoptimal clinical response to imatinib in Asian CML patients.
BACKGROUND:MDR1 gene polymorphisms were demonstrated to be associated with interindividual variability of imatinib response for chronic myeloid leukemia (CML) patients in several studies; however, the results have been inconclusive. MATERIALS & METHODS: To clarify the effect of common MDR1 variants on clinical response to imatinib, we performed a meta-analysis to quantify the accumulated information from genetic association studies. After a thorough search of the published literature, we undertook a meta-analysis to evaluate the effect of MDR1C1236T, G2677T and C3435T polymorphisms on imatinib response. RESULTS: Our pooled data showed a significant association between MDR1C1236T polymorphism and the increasing risk of imatinib resistance in Asian CMLpatients. However, no significant association was found for the MDR1G2677T or C3435T polymorphisms in an Asian CML population as well as a Caucasian CML population. CONCLUSION: The synonymous MDR1C1236T polymorphism might be a risk factor for nonoptimal clinical response to imatinib in Asian CMLpatients.
Authors: Q Zheng; H Wu; Q Yu; D H Dennis Kim; J H Lipton; S Angelini; S Soverini; D Vivona; N Takahashi; J Cao Journal: Pharmacogenomics J Date: 2014-09-23 Impact factor: 3.550
Authors: Kevin G Chen; George E Duran; Mark J Mogul; Yan C Wang; Kevin L Ross; Jean-Pierre Jaffrézou; Lyn M Huff; Kory R Johnson; Tito Fojo; Norman J Lacayo; Branimir I Sikic Journal: Cancer Drug Resist Date: 2020-11-03
Authors: Fatemeh Mohammadi; Mohammad Shafiei; Dlnya Assad; Golale Rostami; Mohammad Hamid; Ali Mohammad Foroughmand Journal: Iran Biomed J Date: 2020-08-25